AxoGen, Inc. (NASDAQ:AXGN)’s share price hit a new 52-week high during trading on Wednesday . The stock traded as high as $19.85 and last traded at $19.85, with a volume of 63,135 shares changing hands. The stock had previously closed at $19.50.

AXGN has been the subject of several recent research reports. Cantor Fitzgerald initiated coverage on AxoGen in a research report on Thursday, June 29th. They set an “overweight” rating and a $18.00 price objective for the company. BidaskClub lowered AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Leerink Swann initiated coverage on AxoGen in a research report on Monday, July 31st. They set an “outperform” rating and a $22.00 price objective for the company. Finally, Roth Capital reissued a “buy” rating and set a $21.00 price objective (up previously from $18.00) on shares of AxoGen in a research report on Tuesday, September 12th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. AxoGen currently has an average rating of “Buy” and a consensus price target of $17.40.

The company’s 50-day moving average is $18.43 and its 200 day moving average is $15.34. The stock’s market capitalization is $651.68 million.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The business had revenue of $15.20 million for the quarter, compared to the consensus estimate of $14.40 million. During the same quarter in the prior year, the company earned ($0.09) EPS. The business’s revenue was up 46.2% compared to the same quarter last year. On average, equities research analysts forecast that AxoGen, Inc. will post ($0.31) EPS for the current fiscal year.

In related news, Director Robert James Rudelius sold 16,143 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $18.00, for a total transaction of $290,574.00. Following the sale, the director now owns 43,273 shares of the company’s stock, valued at $778,914. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 9.33% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of the stock. Parametric Portfolio Associates LLC boosted its position in AxoGen by 0.9% during the first quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 93 shares in the last quarter. Nationwide Fund Advisors boosted its position in AxoGen by 5.5% during the second quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock valued at $249,000 after purchasing an additional 774 shares in the last quarter. Bank of America Corp DE boosted its position in AxoGen by 8.7% during the first quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 814 shares in the last quarter. American International Group Inc. boosted its position in AxoGen by 7.7% during the first quarter. American International Group Inc. now owns 14,941 shares of the medical equipment provider’s stock valued at $156,000 after purchasing an additional 1,068 shares in the last quarter. Finally, UBS Group AG boosted its position in AxoGen by 8.3% during the first quarter. UBS Group AG now owns 16,141 shares of the medical equipment provider’s stock valued at $169,000 after purchasing an additional 1,234 shares in the last quarter. 66.47% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/10/18/axogen-inc-axgn-sets-new-12-month-high-at-19-85.html.

About AxoGen

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Receive News & Stock Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related stocks with our FREE daily email newsletter.